Mechanisms Underlying Metastatic Pancreatic Cancer

被引:6
|
作者
Pitarresi, Jason R. [1 ,2 ]
Rustgi, Anil K. [3 ]
机构
[1] Univ Penn, Dept Med, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Columbia Univ, Irving Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA
关键词
Pancreatic cancer; Epithelial-mesenchymal transition (EMT); Cellular plasticity; Metastasis; Metastatic organotropism; TO-MESENCHYMAL TRANSITION; DUCTAL ADENOCARCINOMA; EPITHELIAL PLASTICITY; CELLS; EMT; PROGRESSION; EXPRESSION; KRAS(G12D); INHIBITOR; COOPERATE;
D O I
10.1007/978-3-030-22254-3_1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma is an overwhelming fatal disease that often presents with overt metastases and ultimately causes the majority of cancer-associated deaths. The mechanisms underlying the metastatic cascade are complex, and research in recent years has begun to provide insights into the underlying drivers of this phenomenon. It has become clear that cancer cells, in particular pancreatic cancer cells, possess properties of plasticity involving bidirectional transition between epithelial and mesenchymal identities. Furthermore, recent work has begun to establish that there are distinct hybrid states between purely epithelial and purely mesenchymal states that cancer cells may reside, in order to thrive at different stages of carcinogenesis. We discuss how this plasticity is important for different phases of the metastatic cascade, from delamination to colonization, and how different epithelial-mesenchymal states may affect metastatic organotropism. In this review, we summarize the current understanding of pancreatic cancer cell plasticity and metastasis, and highlight current model systems that can be used to study these phenomena.
引用
收藏
页码:3 / 10
页数:8
相关论文
共 50 条
  • [31] Systemic Therapy for Metastatic Pancreatic Cancer
    Ettrich, Thomas J.
    Seufferlein, Thomas
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (11)
  • [32] Venous thromboembolism in metastatic pancreatic cancer
    Laderman, Lauren
    Sreekrishnanilayam, Krishnalatha
    Pandey, Ramesh K. K.
    Handorf, Elizabeth
    Blumenreich, Aryeh
    Sorice, Kristen A. A.
    Lynch, Shannon M. M.
    Cheema, Khadija
    Nagappan, Lavanya
    Sosa, Iberia R. R.
    Dotan, Efrat
    Vijayvergia, Namrata
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (06) : 706 - 714
  • [33] OLAPARIB APPROVED FOR METASTATIC PANCREATIC CANCER
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2020, 120 (04) : 22 - 23
  • [34] Sequence therapy in metastatic pancreatic cancer
    Waidmann, Oliver
    Pelzer, Uwe
    Boeck, Stefan
    Waldschmidt, Dirk-Thomas
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2018, 56 (06): : 578 - 582
  • [35] Maintenance Olaparib for Metastatic Pancreatic Cancer
    Charkes, N. David
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (15): : 1491 - 1491
  • [36] Personalization of Chemotherapy for Metastatic Pancreatic Cancer
    Sasahara, Yuriko
    Narimatsu, Hiroto
    Suzuki, Syuhei
    Fukui, Tadahisa
    Sato, Hideyuki
    Shirahata, Nakao
    Yoshioka, Takashi
    CLINICAL MEDICINE INSIGHTS-CASE REPORTS, 2014, 7 : 59 - 61
  • [37] The economic burden of metastatic pancreatic cancer
    Malangone-Monaco, Elisabetta
    Doleh, Yunes
    Cole, Ashley
    Noxon, Virginia
    Antico, Giovanni
    Pishvaian, Michael J.
    PANCREATOLOGY, 2020, 20 (07) : 1434 - 1441
  • [38] Gemcitabine in the treatment of metastatic pancreatic cancer
    Hilbig, Andreas
    Oettle, Helmut
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (04) : 511 - 523
  • [39] The Pathology and Genetics of Metastatic Pancreatic Cancer
    Yachida, Shinichi
    Iacobuzio-Donahue, Christine A.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2009, 133 (03) : 413 - 422
  • [40] Optimal treatment of metastatic pancreatic cancer
    Cunningham, David
    Chong, Irene
    GUT, 2010, 59 (11) : 1454 - 1455